Additionally, in the pathological state of the liver, glucagon-induced acetylation of energy-sensing factors such as signal transducer and activator of transcription–3 (STAT3) provide a potential treatment strategy for liver disease [33] (Table 1). This evidence concerns the gene GCG and liver disorder.